All news

HC Wainwright & Co. reiterates Buy rating on Zenas BioPharma, $44 price target

Alpha Vantage · TradingView · · AI-summarised by FinFlash

HC Wainwright & Co. has reiterated its Buy rating on Zenas BioPharma (ZBIO) with a price target of $44.00, representing a potential upside of 66.7% from its previous closing price. The positive outlook is supported by promising data on obexelimab's efficacy in preventing disease flares and its potential for long-term maintenance therapy in autoimmune conditions.

Read original source

ZBIO company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.